Top three insurers reaped $7.3 billion through their drug middlemen's markups, FTC says
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" prescription price hikes of 1,000% or more.
FTC finds middlemen inflate specialty generic drug prices by billions of dollars
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs between 2017 and 2022,
'Raking in billions': Report shows drug middlemen jack up prices by nearly 8,000%
The U.S. Federal Trade Commission on Tuesday published the second part of its investigation into how prescription drug middlemen are marking up the prices of specialty generic drugs dispensed at their affiliated pharmacies by hundreds—and in some cases,
FTC report shows $7.3 billion in drug price inflation by leading pharmacy benefit managers
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.
FTC releases second report slamming pharmacy benefit managers
Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the controversial drug middlemen as the agency’s first report released last summer — but relies on more data.
FTC takes fresh swipe at drug middlemen, says some prices marked up over 1,000%
The drug middlemen known as pharmacy-benefit managers took another body blow from regulators on Tuesday, as they were criticized for charging way more for some “critical” prescription drugs than it cost them.
PBMs made billions marking up specialty drugs by more than 1,000 percent: FTC
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying the major industry middlemen generate billions in revenue through
FTC Report Highlights Prescription Drug Price Markups by PBMs
A report from the Federal Trade Commission (FTC) has determined that pharmacy benefit managers (PBMs) are linked to significant cost increases for cancer, HIV, and other critical specialty drugs.
New Idaho law targets prescription drug costs through pharmacy benefit manager regulation
A new law that took effect on Jan. 1 regulates some practices of PBMs, which act as middlemen between drug manufacturers, insurance companies and pharmacies.
FTC says pharmacy benefits managers marked-up generic drug prices for $7.3bn gain
Regulator’s report finds companies ‘hiked costs’ for a range of medicines, including cancer and HIV treatments
Largest Pharmacy-Benefit Managers Hiked Up Drug Prices, FTC Says
The largest pharmacy-benefit managers hiked the prices of certain drugs dispensed through their own pharmacies, according to a new report by the Federal Trade Commission released on Tuesday. The markups helped the PBMs reap $7.
penncapital-star5h
Regulator accuses drug middlemen of wild price hikes, possibly steering business to themselves
The Federal Trade Commission on Tuesday released an interim report saying that powerful drug middlemen marked up drugs for ...
City of Columbus sues drug companies over insulin prices
Columbus joins the states of Arkansas, California, Kansas, Kentucky, Minnesota and Mississippi and other cities and counties ...
U.S. district judge in opioid proceedings slams pharmacy middlemen, says they’re trying to stall
The U.S. district judge in Cleveland, Ohio handling a galaxy of claims stemming from the prescription opioid epidemic on ...